The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 13, 2017

Filed:

Jul. 01, 2016
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

David Frendewey, New York, NY (US);

Guochun Gong, Elmsford, NY (US);

Ka-Man Venus Lai, Tarrytown, NY (US);

David M. Valenzuela, Yorktown Heights, NY (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12N 15/87 (2006.01); C12N 5/071 (2010.01); C12N 15/00 (2006.01); C12N 15/85 (2006.01); A01K 67/027 (2006.01); C12N 15/90 (2006.01); C12N 15/873 (2010.01); C12N 9/12 (2006.01); C12N 5/0735 (2010.01);
U.S. Cl.
CPC ...
C12N 15/85 (2013.01); A01K 67/0275 (2013.01); A01K 67/0276 (2013.01); C12N 5/0606 (2013.01); C12N 9/1241 (2013.01); C12N 15/8509 (2013.01); C12N 15/873 (2013.01); C12N 15/907 (2013.01); C12Y 207/07 (2013.01); A01K 2217/07 (2013.01); A01K 2217/075 (2013.01); A01K 2217/206 (2013.01); A01K 2227/105 (2013.01); A01K 2267/03 (2013.01); C12N 2800/22 (2013.01); C12N 2800/30 (2013.01); C12N 2840/102 (2013.01);
Abstract

Targeting constructs and methods of using them are provided for differentiation-dependent modification of nucleic acid sequences in cells and in non-human animals. Targeting constructs comprising a promoter operably linked to a recombinase are provided, wherein the promoter drives transcription of the recombinase in an differentiated cell but not an undifferentiated cell. Promoters include Blimp1, Prm1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and Pax3. Targeting constructs with a cassette flanked on both sides by recombinase sites can be removed using a recombinase gene operably linked to a 3'-UTR that comprises a recognition site for an miRNA that is transcribed in undifferentiated cells but not in differentiated cells. The constructs may be included in targeting vectors, and can be used to automatically modify or excise a selection cassette from an ES cell, a non-human embryo, or a non-human animal.


Find Patent Forward Citations

Loading…